Article released 5 days ago. In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Immunomedics, with a price target of $54.00. The company’s shares closed last Wednesday at $32.20, close to its 52-week high of $33.03.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.